Comparison of the efficacy of thalidomide combined with low-dose rituximab and low-dose rituximab alone in the treatment of steroid-resistant/refractory adult patients with primary immune thrombocytopenia: an open-label trial
The combination of THD LD-RTX represents a promising therapeutic strategy for patients with steroid-refractory or steroid-dependent ITP. Furthermore, baseline NK cell levels may serve as a useful biomarker for predicting treatment response.
Authors
- Chengfu Ji
- Genjie Wang
- Junli Zhang (ORCID: https://orcid.org/0000-0003-1851-4512)
- Ying Tian (ORCID: https://orcid.org/0000-0001-7957-3220)
- Hua Zhou
- Lin Yuan
- Han Shen
- Shuo YANG
- Qingzhu Hu
- Mingfeng Zhao
Institutions
- Tianjin First Center Hospital (CN)
- Shangqiu First People's Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-01-09
- DOI
- https://doi.org/10.3389/fmed.2025.1670736
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China